Výsledky vyhledávání - "Janice Jia Ni Goh"

Translational predictions of phase 2a first-in-patient efficacy studies for antituberculosis drugs

Autor: Jacqueline P. Ernest, Janice Jia Ni Goh, Natasha Strydom, Qianwen Wang, Rob C. van Wijk, Nan Zhang, Amelia Deitchman, Eric Nuermberger, Rada M. Savic

Publikováno v: bioRxiv

BackgroundPhase 2a trials in tuberculosis typically use early bactericidal activity (EBA), the decline in sputum colony forming units (CFU) over 14 days, as the primary outcome for testing the efficacy of drugs as monotherapy. However, the cost of ph

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9a464ad23ca0131b403c0e761628b36f
https://europepmc.org/articles/PMC9882354/

Zobrazit plný text záznamu

Structure-based virtual screening of CYP1A1 inhibitors: towards rapid tier-one assessment of potential developmental toxicants

Autor: Hao Fan, Sebastian Maurer-Stroh, Lit-Hsin Loo, Julian Behn, Cheng-Shoong Chong, Guorui Zhong, Janice Jia Ni Goh

Publikováno v: Archives of Toxicology

Cytochrome P450 1A1 (CYP1A1) metabolizes estrogens, melatonin, and other key endogenous signaling molecules critical for embryonic/fetal development. The enzyme has increasing expression during pregnancy, and its inhibition or knockout increases embr

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7a9f3098df97b9bef126d14a02df7dd8
https://doi.org/10.1007/s00204-021-03111-2

Zobrazit plný text záznamu

Application of Static Modeling in the Prediction of In Vivo Drug–Drug Interactions between Rivaroxaban and Antiarrhythmic Agents Based on In Vitro Inhibition Studies

Autor: Gigi N.C. Chiu, Yanjun Hong, Gopalakrishnan Venkatesan, Eric Chun Yong Chan, Pipin Kojodjojo, Yuanjie Liu, Eleanor Jing Yi Cheong, Janice Jia Ni Goh

Publikováno v: Drug Metabolism and Disposition. 45:260-268

Rivaroxaban, a direct Factor Xa inhibitor, is indicated for stroke prevention in nonvalvular atrial fibrillation (AF). Studies have revealed that the clearance of rivaroxaban is largely attributed to CYP3A4, CYP2J2 metabolism, and P-glycoprotein (P-g

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::09f262cd9661ec675eb667f2d1bbb80b
https://doi.org/10.1124/dmd.116.073890

Zobrazit plný text záznamu

Rivaroxaban With and Without Amiodarone in Renal Impairment

Autor: Yanjun Hong, Pipin Kojodjojo, Eleanor Jing Yi Cheong, Eric Chun Yong Chan, Janice Jia Ni Goh

Publikováno v: Journal of the American College of Cardiology. 71:1395-1397

Rivaroxaban undergoes hepatic metabolism by cytochrome P450 (CYP) enzymes (CYP3A4 and CYP2J2) and renal excretion via P-glycoprotein (P-gp)–mediated secretion [(1)][1]. Amiodarone and its main metabolite N -desethylamiodarone (NDEA) inhibit CYP3A4

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::845ec153ca0d8facf7016b83ae67a74f
https://doi.org/10.1016/j.jacc.2018.01.044

Zobrazit plný text záznamu

Comparison of rivaroxaban concentrations between Asians and Caucasians and their correlation with PT/INR

Autor: Jernice Wan Xin Aw, Janice Jia Ni Goh, Alan Yean Yip Fong, Lee Len Tiong, Yingying Lin, Hobart Owen Ng Tsai, Doreen Su-Yin Tan

Publikováno v: Journal of thrombosis and thrombolysis. 46(4)

The objectives of this study are to compare steady-state trough (Cmin,ss) and peak (Cmax,ss) concentrations of rivaroxaban between Asians and Caucasians and to evaluate the relationship between rivaroxaban concentrations and prothrombin time/internat

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0249a9318408f2873bab90799eacec33
https://pubmed.ncbi.nlm.nih.gov/30155672

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání